UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Blood, 2021-07, Vol.137 (26), p.3676-3681

2021

Volltextzugriff (PDF)

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Journal of clinical oncology, 2013-07, Vol.31 (20), p.2540-2547

2013

Volltextzugriff (PDF)

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Blood, 2015-03, Vol.125 (12), p.1932-1935

2015

Volltextzugriff (PDF)

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Blood, 2014-08, Vol.124 (8), p.1296-1299

2014

Volltextzugriff (PDF)

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Haematologica (Roma), 2016-02, Vol.101 (2), p.e69-e71

2016

Volltextzugriff (PDF)

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Histopathology, 2011-01, Vol.58 (1), p.90-105

de Tute, Ruth M

2011

Volltextzugriff (PDF)

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3945-3955

2023

Volltextzugriff (PDF)

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Journal of clinical oncology, 2022-09, Vol.40 (25), p.2889-2900

2022

Volltextzugriff (PDF)

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.31-39

2016

Volltextzugriff (PDF)

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

The New England journal of medicine, 2008-08, Vol.359 (6), p.575-583

2008

Volltextzugriff (PDF)

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Bone marrow transplantation (Basingstoke), 2024-03, Vol.59 (3), p.431-434

2024

Volltextzugriff (PDF)

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort

BMJ open, 2021-02, Vol.11 (2), p.e041296-e041296

2021

Volltextzugriff (PDF)

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.54-60

2016

Volltextzugriff (PDF)

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Clinical lymphoma, myeloma and leukemia, 2013-04, Vol.13 (2), p.211-213

2013

Volltextzugriff (PDF)

Reply to M. Roschewski et al

Journal of clinical oncology, 2014-02, Vol.32 (5), p.476-477

2014

Volltextzugriff (PDF)

Defining IgM multiple myeloma

American journal of hematology, 2011-08, Vol.86 (8), p.717-717

2011

Volltextzugriff (PDF)

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Blood, 2022-11, Vol.140 (Supplement 1), p.7032-7033

2022

Volltextzugriff (PDF)

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

The New England journal of medicine, 2024-01, Vol.390 (4), p.326-337

2024

Volltextzugriff (PDF)

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Cytometry. Part B, Clinical cytometry, 2016-01, Vol.90 (1), p.61-72

2016

Volltextzugriff (PDF)

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

Leukemia, 2024-04, Vol.38 (4), p.822-828

2024

Volltextzugriff (PDF)

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Blood, 2023-11, Vol.142 (Supplement 1), p.881-881

2023

Volltextzugriff (PDF)

1 – 25 von 109

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBritish Journal Of Haematology

Zeitschrift / SeriePlos Medicine

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(97)

Publikationsform

Sprache

Englisch
(109)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Novel somatic mutations in UBA1 as a cause of VEXAS syndrome

Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study

Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reduction

Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysis

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)

Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimen

Flow cytometry and its use in the diagnosis and management of mature lymphoid malignancies

Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma

Minimal Residual Disease After Autologous Stem-Cell Transplant for Patients With Myeloma: Prognostic Significance and the Impact of Lenalidomide Maintenance and Molecular Risk

Consensus guidelines on plasma cell myeloma minimal residual disease analysis and reporting

Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia

Impact of minimal residual disease (MRD) in salvage autologous stem cell transplantation for relapsed myeloma: results from the NCRI Myeloma X (intensive) trial

Upfront autologous haematopoietic stem-cell transplantation versus carfilzomib–cyclophosphamide–dexamethasone consolidation with carfilzomib maintenance in patients with newly diagnosed multiple myeloma in England and Wales (CARDAMON): a randomised, phase 2, non-inferiority trial

Health impact of monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B-cell lymphocytosis (MBL): findings from a UK population-based cohort

Risk and response adapted therapy following autologous stem cell transplant in patients with newly diagnosed multiple myeloma (RADAR (UK-MRA Myeloma XV Trial): study protocol for a phase II/III randomised controlled trial

Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service

Frailty-adjusted therapy in Transplant Non-Eligible patients with newly diagnosed Multiple Myeloma (FiTNEss (UK-MRA Myeloma XIV Trial)): a study protocol for a randomised phase III trial

Immunoglobulin M Concentration in Waldenström Macroglobulinemia: Correlation With Bone Marrow B Cells and Plasma Cells

Reply to M. Roschewski et al

Defining IgM multiple myeloma

High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma

Long-term outcomes by bone marrow B-cell depletion from the R2W trial of bortezomib with cyclophosphamide and rituximab in Waldenstrőm macroglobulinaemia

Ultra High-Risk Multiple Myeloma Patients with Multi-Hit Tumours and SKY92 High Risk Signature Are at Increased Risk of Early Relapse Even When Treated with Extended Intensified Induction and Consolidation - Results from the Optimum/Muknine Trial

Aktive Filter

Suchergebnisse filtern